Non-Hodgkin's lymphoma (NHL) is a heavily segmented disease, with a variety of aggressive and indolent subtypes arising from B- or T- lymphocytes. Depending on subtype, chemoimmunotherapy combinations are often used in first-line settings, while targeted therapies (BTK or PI3K inhibitors) and immunotherapies (CART) are standard-of-care for relapsed/refractory NHL. The complex treatment algorithms and diverse MOAs being investigated for NHL create a vibrant and dynamic clinical landscape, with many opportunities for novel agents to improve patient outcomes.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in non-hodgkin’s lymphoma to help guide strategic and tactical commercial development decisions for market participants.